Novo Nordisk A/S

NYSE:NVO

Drug Manufacturers - General

Healthcare
$39.43 -1.09%

-$0.48 today

Market cap
$173.82B
Beta
0.35
P/E (TTM)
10.2
EPS (TTM)
$27.45
Dividend yield
4.18%
52W Low $35.12High $74.38

Volume 16.12M

Average 16.05M

NVO Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

Novo Nordisk A/SNYSE: NVO

Other Income / Expenses · Q2 FY2026 · quarter ended Jun 2026

Other income / expenses turns negative

Q2 FY2026 other income / expenses was -DKK 186M, compared with DKK 356M a year earlier. Trailing-twelve-month other income / expenses was DKK 6.65B.

Context

  • Other income / expenses amounted to 0.9% of revenue in FY2025, up 0.5 pp from a year earlier.
  • Other income / expenses increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly other income / expenses holds near -DKK 186M or moves back toward the trailing-twelve-month quarterly average of DKK 1.66B.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
-DKK 186M-107.3% QoQ
Last fiscal yearDec 2025
DKK 2.88B+351.0% YoY
LTMJun 2026
DKK 6.65B+429.3% YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-152.2%——
1 year+351.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

DKK · from the income statement

Latest · FY2025
2.88B DKK
Year-over-year change
+351.0%
4-year CAGR
+60.3%

Other Income / Expenses vs competitors

How NVO compares with its peers on the latest reported figures

  • Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +429.3% is the highest of 10, against a peer median of -109.5%.
  • Other income / expenses amounts to 2.0% of revenue for NVO, versus a peer median of 7.5%.
NVO Competitors
Other Income / Expenses for NVO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NVONovo Nordisk A/SLTM Jun 2026DKK 6.65B DKK+429.3%—2.0%
GSKGSK plcLTM Jun 2026-£969M GBP-93.0%—2.9%
AZNAstraZeneca PLCLTM Sep 2026-$1.46B USD-7.3%—2.4%
SNYSanofiLTM Jun 2026-€2.04B EUR-845.8%—4.2%
AMGNAmgen Inc.LTM Jun 2026-$2.36B USD-212.3%—6.2%
MRKMerck & Co., Inc.LTM Jun 2026-$5.11B USD-128.1%—7.7%
LLYEli Lilly and CompanyLTM Jun 2026-$6.01B USD-7.8%—7.5%
JNJJohnson & JohnsonLTM Sep 2026-$7.79B USD-204.5%—7.8%
ABBVAbbVie Inc.LTM Sep 2026-$10.64B USD-44.2%—16.1%
PFEPfizer Inc.LTM Jun 2026-$12.81B USD-109.5%—20.1%
Peer median (excluding NVO) —-109.5%—7.5%

Competitors are the stored peer set for NVO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

DKK
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue140.8B176.95B232.26B290.4B309.06B
Cost of Revenue23.66B28.45B35.77B44.52B58.79B
Gross Profit117.14B148.51B196.5B245.88B250.28B
Gross Margin83.2%83.9%84.6%84.7%81.0%
Research & Development17.77B24.05B32.44B48.06B52.04B
Selling, General & Admin41.06B50.68B61.6B67.38B70.28B
Operating Expenses58.5B73.7B93.92B117.54B122.62B
Depreciation & Amortization6.03B7.36B9.41B19.11B21.98B
EBITDA65.39B76.8B114.63B147.94B156.73B
EBITDA Margin46.4%43.4%49.4%50.9%50.7%
Operating Income58.64B74.81B102.57B128.34B127.66B
Operating Margin41.7%42.3%44.2%44.2%41.3%
Interest Income231M239M1.07B1.84B1.27B
Interest Expense289M378M542M1.64B4.21B
Other Income / Expenses436M(5.75B)2.1B(1.15B)2.88B
Income Before Tax59.08B69.06B104.67B127.19B130.54B
Pre-Tax Margin42.0%39.0%45.1%43.8%42.2%
Income Tax Expense11.32B13.54B20.99B26.2B28.11B
Net Income47.76B55.53B83.68B100.99B102.43B
Net Margin33.9%31.4%36.0%34.8%33.1%
EPS (Basic)10.4012.2618.6722.6723.06
EPS (Diluted)10.3712.2218.6222.6323.03
Weighted Avg Shares4.59B4.53B4.48B4.45B4.45B
Weighted Avg Shares (Diluted)4.61B4.54B4.49B4.46B4.45B

Novo Nordisk A/S

NYSE:NVO

Intrinsic Alpha fair value

Locked

Current Price

$39.43

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.